ArticleTranslational lung cancer research2022

The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study.

Bolin Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.